Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 4/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.34 |
| ▸ | ELOVL3 | Q9HB03 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 2/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPC | P11150 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1339934 | 0.90 | PTGDR2 (0.39) | GRM4 | |
| SCHEMBL1340912 | 0.90 | GRM4 (0.35) | GRM4CSNK1DBRAFKDRSORT1 | |
| SCHEMBL1342188 | 0.89 | GRM4 (0.37) | GRM4CSNK1DBRAFKDRSORT1 | |
| SCHEMBL1338714 | 0.89 | GRM4 (0.36) | GRM4 | |
| SCHEMBL1341703 | 0.89 | GRM4 (0.36) | GRM4CSNK1DBRAFKDRSORT1 | |
| SCHEMBL1342944 | 0.89 | GRM4 (0.38) | GRM4 | |
| SCHEMBL1341812 | 0.89 | GRM4 (0.36) | GRM4 | |
| SCHEMBL1343496 | 0.87 | CSNK1D (0.38) | CSNK1DBRAFKDRCCR2LIPC | |
| SCHEMBL1341114 | 0.87 | KMT2A (0.39) | GRM4 | |
| SCHEMBL1340258 | 0.87 | MAPT (0.34) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | GRM4 2551/4885CSNK1D 1591/4885BRAF 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.